Publications
43
Citations
280
Est. group size
~10
Recurring co-author estimate
Active years
14
Publishing since 2013
Typically publishes in teams of ~14 · 16% small-team papers (≤3 authors) · across 14 venues
- Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database
Clinical Genitourinary Cancer · 2026
- Impact of HER2 expression and <i>ERBB2</i> alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
Journal of Clinical Oncology · 2026
- Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
Journal of Clinical Oncology · 2026
- Effect of upfront dose reductions on efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.
Journal of Clinical Oncology · 2026
- Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis.
Journal of Clinical Oncology · 2026
- Impact of abiraterone versus enzalutamide on depression and anxiety in hormone-sensitive prostate cancer (HSPC).
Journal of Clinical Oncology · 2026
- Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Journal of Clinical Oncology · 2026
- Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)
Research Square · 2026
- Clinical and genomic predictors of outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
Journal of Clinical Oncology · 2026
- Risk and patterns of recurrence for patients (pts) with advanced urothelial carcinoma (aUC) metastatic to liver after response to enfortumab vedotin + pembrolizumab (EVP).
Journal of Clinical Oncology · 2026
- Effect of on-treatment dose adjustments on the efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.
Journal of Clinical Oncology · 2026
- Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study
European Urology · 2025
- Controversies in metastatic hormone‐sensitive prostate cancer
Cancer · 2025
- 3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study
Annals of Oncology · 2025
- Efficacy of erdafitinib before or after enfortumab vedotin in <i>FGFR3</i> -altered advanced urothelial cancer: analysis of the UNITE collaborative study
The Oncologist · 2025
- Journal of Clinical Oncology×16
- Annals of Oncology×4
- The Oncologist×2
- Cancer×2
- Clinical Genitourinary Cancer×2
- Cindy Jiang
Medicine · University of Michigan
- Eugene Oh
Medicine · University of Michigan
- Ajjai Alva
Medicine · University of Michigan
- Amir Mortazavi
Medicine · The Ohio State University
- Phillip L. Palmbos
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile